The #FDA decision to hold an Advisory Committee for #donanemab is likely due in part to the #AntiAmyloid drug's unique trial design. Our CSO, @a_hfillit, discusses the #biomarker-powered trial that used #tau staging and stopping rules in @biospace: bit.ly/4acT0HE
0
1
7
703
0